Advances in the risk relationship between glucagon-like peptide-1 receptor agonists and diabetic retinopathy
10.3760/cma.j.cn511434-20211217-00707
- VernacularTitle:胰高血糖素样肽-1受体激动剂与糖尿病视网膜病变风险关系研究进展
- Author:
Huiwen TAN
1
;
Danting LI
;
Meixia ZHANG
Author Information
1. 四川大学华西医院内分泌代谢科，成都 610041
- Keywords:
Diabetic retinopathy;
Glucagon-like peptide-1 receptor agonist;
Multi-effect protection;
Risk;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2023;39(11):943-948
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic retinopathy (DR) is one of the most serious complications of diabetes mellitus. Severe diabetic macular edema or proliferative retinopathy may lead to impaired vision or even blindness in diabetic patients. The glucagon-like peptide-1 receptor agonist (GLP-1RA) is now commonly used as novel glucose-lowering agents in the clinical management of type 2 diabetes, but the rapid glycaemic changes associated with the use of the GLP-1RA may aggravate the risk of an increase in the occurrence of short-term potential DR. Potential effects and mechanisms of DR include oxidative stress, vascular endothelial growth factor, inflammation, retinal neurodegeneration, and other cytokines.Whether GLP-1RA leads to the increased risk of DR remains controversial. More basic and clinical studies are needed with the aim of further clarifying the correlation between GLP-1RA and DR risk.
